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The podocyte is one of the two cell types that contribute to the formation of the glomerular
filtration barrier (GFB). It is a highly specialized cell with a unique structure.The key feature
of the podocyte is its foot processes that regularly interdigitate. A structure known as the
slit diaphragm can be found bridging the interdigitations. This molecular sieve comprises
the final layer of the GFB. It is well accepted that the podocyte is the target cell in the
pathogenesis of nephrotic syndrome. In nephrotic syndrome, the GFB no longer restricts
the passage of macromolecules and protein is lost into the urine. A number of phenotypic
and morphological changes are seen in the diseased podocyte and in the literature these
have been described as an epithelial–mesenchymal transition (EMT). However, there is
a growing appreciation that this term does not accurately describe the changes that are
seen. Definitions of type-2 EMT are based on typical epithelial cells. While the podocyte is
known as a visceral epithelial cell, it is not a typical epithelial cell. Moreover, podocytes have
several features that are more consistent with mesenchymal cells. Therefore, we suggest
that the term podocyte disease transformation is more appropriate.
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INTRODUCTION
The podocyte is thought to be the target cell in the pathogen-
esis of nephrotic syndrome. The term “podocytopathy” is being
increasingly used to describe disease that has arisen due to insult
or injury to the podocyte. Minimal change nephropathy (MCN),
focal segmental glomerulosclerosis (FSGS), diffuse mesangial scle-
rosis (DMS), and collapsing glomerulopathy (CG) are all thought
to be podocytopathic nephrotic diseases (1). Irrespective of the
cause, podocytes demonstrate dramatic morphological differences
when there is nephrotic range proteinuria (2). Actin cytoskeleton
rearrangement, slit diaphragm loss, and more cuboidal morphol-
ogy are all hallmark features of the diseased podocyte (2). The
field has tended to refer to this loss of typical phenotype as an
epithelial–mesenchymal transition (EMT) event (3–5).
However, EMT is a highly plastic and reversible process: indeed,
the word “transition” was chosen deliberately to reflect this tran-
sient nature. The phenotypic and morphological changes seen
in diseased podocytes are only reversible if the insult is not
very severe. In minimal change disease, the disease phenotype is
reversible following glucocorticoid therapy. However, in FSGS, the
changes in morphology and phenotype are not only irreversible
but progressive (6). Therefore, using the term EMT implies an
innate reversibility, which is not strictly accurate in the case of
the podocyte. Therefore, it is important to reassess the extent to
which the term EMT accurately describes the transposition from
the healthy to the diseased podocyte morphology. Additionally,
the podocyte is not a typical epithelial cell. Despite podocytes
also being known as visceral epithelial cells, they retain several
mesenchymal features (spindle shaped morphology and high lev-
els of matrix interaction) and lack archetypal epithelial markers
(cell–cell contacts that are based predominantly on P rather than
E-cadherin). Therefore, the podocyte fails to demonstrate the
emblematic features of EMT. If the change in podocyte morphol-
ogy and phenotype seen in disease does not fulfill the accepted
criteria for an EMT event and is not necessarily transient in nature,
then the usefulness of this term in this context must be questioned.
Immortalized podocytes in vitro respond to the classic inducer
of EMT, TGF-B1. Following TGF-B1 treatment, human podocytes
in vitro demonstrate increased levels of α-SMA, cadherin switch
from P-cadherin to N-cadherin, and expression of the main effec-
tor transcription factors of EMT: SNAIL and SLUG (7). Similar
phenotypic changes are seen in mouse podocytes in vitro when
exposed to TGF-B1. Again suppression of P-cadherin along with
suppression of ZO-1 and nephrin with concomitant upregulation
of desmin, fibronectin, and collagen I is observed (8). In vitro,
following 24 h exposure to TGF-B1, human podocytes lose their
highly arborized morphology and adopt a more cobblestone-like
morphology. The existence of similar phenotypic changes in both
mouse and human podocytes in response to TGF-B1 is indicative
of an evolutionarily conserved disease mechanism.
The pathological effects of such phenotypic changes within a
cell-type, such as the podocyte, are severe. Foot process efface-
ment is linked to a diminished ability to restrict urinary protein
loss. This leads to runaway proteinuria and nephrotic syndrome.
Effaced podocytes have less contact with the glomerular basement
membrane, making podocyte loss much more likely. Additionally,
the increased synthesis of extracellular matrix (ECM) components
such as fibronectin and collagen I may contribute to GBM thick-
ening. These are all hallmark features of diabetic nephropathy (9).
FSP1 is a fibroblast (mesenchymal) marker, which has been
found in podocytes from patients with diabetic nephropathy.
Healthy podocytes do not express FSP1; therefore, de novo
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expression of a mesenchymal marker is a pathological change in
phenotype. Moreover, the frequency of FSP1+ podocytes in the
urine has been linked to disease severity (8). FSP1+ podocytes
have also been found in the glomeruli of FSGS patients (10).
The term EMT is over simplistic in this context, and does not
encapsulate the process that is seen in the disease state in vivo and
disease models in vitro. Broadly speaking, the morphological and
phenotypic changes seen in diseased podocytes appear to be an
EMT type event. However, in order for the assertion that this is an
EMT event to be accurate, one must first consider to what extent
the changes seen correlate with the definition of EMT.
THE PODOCYTE: A SPECIALIZED CELL
The podocyte is a highly specialized cell that is situated on the
outer surface of the GBM. It comprises three structurally and
functionally unique segments. These are known as the cell body,
the major process, and the foot process (11). The cell body,
the major processes, and the foot processes share a common
actin cytoskeleton contractile apparatus similar to that found in
smooth muscle cells or pericytes (11). The foot processes extend
from the major processes and cover the GBM. Neighboring foot
processes interdigitate, and where this occurs a modified cell-
to-cell junction known as the slit diaphragm is formed (12).
The slit diaphragm forms the final layer of the glomerular fil-
tration barrier (GFB) and has both charge and size selective
properties (13).
The foot processes are the main functional unit of the podocyte.
These contain loops of filamentous actin (F-actin) that can be
assembled, disassembled, and bundled together in response to the
changing requirements of the foot process. The tensile strength
of F-actin and its concentration in the foot processes enable the
podocyte to withstand the pressure of glomerular flow (14). It
is this ability of actin, to be soluble as a monomer and then
rapidly polymerize to provide structure and support that allows
the redistribution of the podocytes foot processes. Bivalent mole-
cules, such as α-actinin-4 and dystrophin can link bundled actin
fibers for added strength (15). There are more than 100 proteins
that are involved in the regulation of actin filament formation
and breakdown indicating that these are essential procedures (16).
The importance of the actin cytoskeletal regulation in the proper
functioning of the podocyte is indicated by the number of so-
called “nephrotic” genes whose protein products act on the actin
cytoskeleton (17) (Table S1 in the Supplementary Material).
Such is the importance of the podocyte and the slit diaphragm
in particular that there are multiple monogenic mutations that
cause nephrotic syndrome as shown in Table S1 of Supplementary
Material.
Structural and functional defects in the GFB result in an inabil-
ity to restrict urinary protein loss. Nephrotic syndrome is defined
by the triad of proteinuria, hypoalbuminemia, and edema. Pro-
teinuria is defined by presence of non-physiological levels of a
mixture of proteins in the urine (>200 mg/l) (20). However, in
clinical practice, the albumin–creatinine ratio is more likely to
be employed as it accounts for differences in urine dilution, i.e.,
a level of >30µg/mg demonstrates proteinuria (21). Structural
and functional defects in the GFB result in an inability to restrict
urinary protein loss.
Podocytes are terminally differentiated cells meaning that they
are unable to proliferate. This lack of podocyte proliferation limits
their capacity to recover from any damage. Therefore, podocyte
injury is thought to be central to nephrotic syndrome patho-
genesis. The range of podocyte injuries that can play a role in
nephrotic syndrome pathogenesis is collectively referred to as
podocytopathies. Many of these podocytopathies are caused by
mutations in key genes. These genes are central to podocyte
function; encoding either slit diaphragm proteins, transcription
factors, or signaling mediators. The genetic causes of nephrotic
syndrome are discussed in detail in an excellent review by Hilde-
brandt (17). In addition to genetic podocytopathies, there are
also reactive podocytopathies. In these reactive podocytopathies,
the podocyte is damaged by mediators in the microenviron-
ment (1). These extrinsic podocyte stressors can be from several
sources. They can be viral, toxic, immune-mediated, mechanical,
or metabolic disorder derived.
EPITHELIAL–MESENCHYMAL TRANSITION
It is well accepted that a loss of the highly specialized podocyte
structure limits the capacity of the final layer of the GFB to restrict
urinary protein loss. The changes seen in diseased podocytes could
be due to an EMT event.
It has been posited in the literature that since podocytes
develop from mesenchymal cells via a mesenchymal–epithelial-
transition (MET) event, it is reasonable to assume that the loss
of mature podocyte characteristics is the reverse of this process
(22). Glomerular development consists of four stages as follows:
the vesicle stage, the S-shaped body stage, the capillary loop stage,
and the maturation stage (23). The early podocytes can first be dis-
tinguished as a layer of cells at the proximal end of the S-shaped
body. During this stage, the podocytes develop from the colum-
nar epithelial cells (24). In turn, the columnar epithelial cells arise
from the metanephric mesenchyme via a MET event (25). At this
point, the podocytes express specific podocyte markers such as
Wilms’ tumor suppressor (WT1) and nephrin (26, 27). As the
capillary loops form, the podocyte progenitors lose their lateral
cell–cell contacts and begin to migrate. As the capillary loop stage
progresses, the podocyte foot processes form. At this point, expres-
sion of the slit diaphragm proteins, nephrin, podocin, and CD2AP
can be seen (28–30).
Epithelial-to-mesenchymal transition is a tightly regulated
process by which epithelial cells lose their hallmark epithelial char-
acteristics and gain the features of mesenchymal cells. EMT can be
initiated in response to circulating mediators such as TGF-B1 (31,
32). During the process of EMT, the podocytes should lose their
epithelial polarity, the cell-to-cell junctions (the slit diaphragm)
will be altered, and the actin cytoskeleton will be rearranged (33).
Following stimulation with TGF-B1, podocytes lose expression of
nephrin and ZO-1 (34). As important slit diaphragm proteins, the
loss of nephrin and ZO-1 expression is detrimental to the function
of the podocyte. Not only does TGF-B1 lead to loss of epithelial
characteristics in podocytes (as evidenced by the loss of nephrin
expression) but also an increase in mesenchymal characteristics.
Desmin is one such mesenchymal marker that is upregulated by
TGF-B1, moreover, desmin upregulation by podocytes is seen in
glomerular diseases where podocyte damage is a key feature (35).
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These changes have severe consequences for the structure and
function of the podocyte cell. The loss of epithelial cell–cell junc-
tions during EMT is best represented by a loss of the slit diaphragm
in the diseased podocyte. As previously described, podocytes
demonstrate a clear change in their morphology and phenotype
in the diseased state. Expression of the slit diaphragm is lost and
the foot processes are effaced. However, does the loss of essential
podocyte features seen in disease and disease models, both in vivo
and in vitro, respectively, represent a typical EMT event?
Epithelial–mesenchymal transition has been categorized into
three types: type 1, associated with implantation, embryo for-
mation, and organ development, type 2, associated with wound
healing tissue regeneration and organ fibrosis, and type 3, which
is associated with cancer metastasis and progression (36). The dis-
tinctions between these subtypes of EMT are outside the scope of
this review but are extensively covered in a review by Kalluri and
Weinberg (36). For the purposes of this review, EMT will now be
a reference to type-2 EMT. The criteria for type-2 EMT are listed
in Table 1.
The changes in morphology and phenotype between healthy
and diseased podocytes only partially satisfies most of the cri-
teria for type-2 EMT and does not fit at all with the rest. The
table demonstrates quite clearly the inaccuracies of describing this
process as EMT. For instance, one of the criteria for type-2 EMT
is a cadherin switch from E-cadherin to N-cadherin. While the
podocytes do undergo a cadherin switch in the diseased state, this
is from P-cadherin to N-cadherin. No evidence could be found in
the literature for podocytes expressing DDR2 or HSP47. Neither
there is clear evidence for the nuclear translocation of TWIST. Oth-
erwise, it is the lack of typical epithelial phenotype in podocytes
that precludes them from matching this definition of EMT.
First of all, podocytes are atypical epithelial cells. While it is
the case that podocytes demonstrate epithelial features, such as
clear apical–basal cell polarity, they also exhibit mesenchymal fea-
tures such as vimentin and intermediate filament expression (16).
They also express features of differentiated mesenchymal cells, in
particular smooth muscle actin, akin to a pericyte phenotype (42).
High migration capacity is a mesenchymal feature, while low
invasive capacity is an epithelial feature, again demonstrating
the dichotomous nature of the podocyte. The healthy podocyte
maintains a dynamic range within which motility is regulated
(43). It has been shown that plasma from patients with active
FSGS significantly increases podocyte motility in vitro (44). The
insult caused by the disease is increasing the mesenchymal char-
acteristic of the podocyte. These hypermotile podocytes are not
invasive due to the location of the podocytes on the outside of the
GBM. The flux of hyperfiltrate through the GFB leads to a loss
of podocytes in the urine. Indeed, as mentioned previously, viable
urinary podocytes have been found with mesenchymal fibroblastic
markers such as FSP1 (25).
Table 1 | Hallmark characteristics of EMT.
Criteria Evidence in the literature Criteria met?
Novel FSP1 and DDR2
expression associated with
basement membrane
disruption
When podocytes are exposed to high glucose concentration in vitro, they demonstrate a clear
upregulation of FSP1 (37). Urinary podocytes from diabetic nephropathy patients are FSP1+ (5).
Moreover, ectopic overexpression of the known EMT inducer TGF-B1 in the glomerulus stimulates
FSP1 in the podocyte (38)
Partially
Increased expression of
HSP47, collagen 1 (α1),
collagen 2 (α2), or vimentin
HSP47 is a marker of collagen producing cells and has been found in crescentic cells but not in
podocytes in vivo or in vitro. TGF-B1, a potent EMT inducer stimulates collagen 1 expression in mouse
podocytes (8). Although mature podocytes express vimentin, the expression increases following
TGF-B1 treatment in vitro (39)
Partially
Cadherin switch from
E-cadherin to N-cadherin
The typical switch from E- to N-cadherin expression is not seen since mature podocytes do not
express E-cadherin (40). They do, however, express P-cadherin. A switch from P-cadherin to N-cadherin
is seen following TGF-B1 treatment (7)
No
Nuclear relocalization of
CBF-A or B-catenin or new
expression of SNAIL, SLUG,
or TWIST
Nuclear translocation of beta-catenin is seen in experimental models of nephrotic syndrome both
in vitro and in vivo and also in diabetic nephropathy (41). Wnt signaling is responsible for the
translocation of beta-catenin and plays an important role in podocyte injury and proteinuria (41). TGF-B1
treatment stimulates SNAIL expression in vitro. Additionally, ectopic expression of SNAIL induces
changes in podocyte phenotype consistent with EMT (8). SLUG is also expressed following TGF-B1
treatment in vitro (7)
Partially
Loss or reduction of epithelial
cell markers
The podocyte dedifferentiation seen in response to TGF-B1 treatment is associated with a reduction in
epithelial markers such as ZO-1 and P-cadherin (8, 39)
Partially
Spindle shape morphology
with redistribution of stress
fibers and loss of polarity
Podocytes have a spindle-like arborized morphology when fully differentiated. This morphology is lost
following insult. A loss of apical–basal polarity leads to the mislocalization of nephrin and concomitant
proteinuria. This loss of polarity has not been seen in models of EMT either in vitro or in vivo
No
The dedifferentiation of podocytes seen in podocytopathic nephrotic syndromes only partially satisfies some of the criteria for a type-2 EMT transition. Clearly, the
morphological and phenotypic changes seen in diseased podocytes are not obtained via a type-2 EMT event.
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Podocytes express P-cadherin instead of E-cadherin; again
this is atypical for an epithelial cell (7, 45). The generation of
a spindle-like morphology is indicative of a mesenchymal phe-
notype. However, normal podocytes both in vitro and in vivo
have a highly arborized structure that is consistent with the
aforementioned spindle-like morphology. Following dedifferen-
tiation, the podocyte actin cytoskeleton rearrangement causes
foot process effacement leading to the morphology seen in
Figure 1. This effaced morphology could be described as anal-
ogous to the typical epithelial “cobblestone” morphology. In
this way, following dedifferentiation, podocyte morphology goes
from the mesenchymal-like highly arborized morphology to
the epithelial-like “cobblestone” morphology. The epithelial and
mesenchymal characteristics of the podocyte are summarized in
Figure 1.
Therefore, when describing podocyte dedifferentiation, one
must be careful to consider to what differential state the podocyte
is reverting. A partial reversal of the mature, partially mesenchymal
state to a more immature epithelial state seen during the S-shaped
body, and capillary loop stages of development could be termed as
MET. However, complete dedifferentiation to the “mesenchymal
rest” state of development could also conceivably occur, and be
more accurately described as EMT, though in neither case is the
terminology adequately nuanced.
The terminology “EMT” was adapted from the original term
“epithelial–mesenchymal transformation” in order to emphasize
the transient nature of this mechanism and the potential for its
reversal (46). Clearly, the podocyte is not the average epithelial cell
and its dedifferentiation does not entirely fit with the definition of
EMT outlined in this article. This is more than simply a semantic
argument. Evidently, mediators such as TGF-B1 can instigate EMT
and induce podocyte dedifferentiation that is at least reminiscent
of EMT. However, by constraining the conceptualization of this
process by only thinking in terms of EMT, novel mediators and dis-
ease processes causing podocyte dedifferentiation may be missed.
In light of the criticisms of this term to describe podocyte dedif-
ferentiation in disease as EMT, perhaps the term podocyte disease
transformation (PDT) is more appropriate. With transformation
reflecting that PDT is less transient than EMT.
GENETIC FORMS OF NEPHROTIC SYNDROME AND EMT
Single gene defects causing NS tend to cause irreversible podocyte
damage. This is to be expected since many of the genes that are
known to cause nephrotic syndrome express proteins that are
key components of the slit diaphragm (nephrin and podocin)
or are essential to the specialized architecture of the podocyte
(such as alpha actinin IV). However, the incorporation of transi-
tion in this term is deliberate. The diseased podocyte phenotype
can be transient. Nephrotic syndrome is often treated with glu-
cocorticoids and/or calcineurin inhibitors both of which have
been shown to have direct effects on the actin cytoskeleton of
the podocyte (47–49). One key renal developmental gene, known
to cause NS when mutated, has been shown to result in features
of podocyte dedifferentiation. This is WT1, a transcription factor
both highly expressed and necessary for renal development (50),
yet only expressed in the podocyte in the mature kidney. Mouse
models of the human disease resulting from WT1 mutations,
Denys–Drash Syndrome (DDS), reveal loss of podocyte ZO-1
expression and upregulation of podocyte TGF-B (51). Further-
more, loss of WT1 and re-expression of PAX2 and cytokeratin in
podocytes have been described in cellular lesions in FSGS biop-
sies, implying an epithelial switch during acquired disease (52).
Our own data examining the phenotype of conditionally immor-
talized podocytes from children with DDS confirms re-expression
of PAX2, but also clear mesenchymal features suggestive of com-
plete dedifferentiation (unpublished results). Thus, WT1 may be
a key regulator of podocyte EMT both developmentally and as a
target in disease.
The extracellular domain of nephrin forms the protein scaf-
fold of the slit diaphragm (53). There are eight IgG-like motifs
in the extracellular domain each of which contains two cysteine
residues that are bound to each other via disulfide bridges. In addi-
tion, there are three “free” cysteine residues per nephrin molecule
that are available to form disulfide bridges with bordering nephrin
molecules (54). In this way, nephrin forms the scaffold for the slit
diaphragm. The extracellular domain of nephrin interacts with
other proteins in order to maintain the integrity of the barrier.
Two such proteins are Neph 1 and Neph 2 (55). Clearly, the loss
of most of the extracellular domain, as in patients with the Fin-
major mutation, has massive implications for the formation of the
slit diaphragm (56). The cytoplasmic domain of nephrin, of which
part is missing in patients with the Fin-minor mutation, plays a
role in the maintenance of the structural and functional capa-
bilities of nephrin (56). The cytoplasmic domain also connects
nephrin, and hence the slit diaphragm to the actin cytoskeleton
of the foot process (57). It has been suggested that nephrin can
bind directly to the actin cytoskeleton of the foot process via its
cytoplasmic domain, while Yuan and colleagues have shown that
nephrin is at least capable of binding to actin (58).
Podocin comprises 383 amino acids and has a hairpin structure
such that both the C and N terminus are cytoplasmic (59). It is a
raft-associated constituent of the foot process membrane that is
localized at the insertion of the slit diaphragm itself (29). Within
the raft, podocin can form oligomers, which lead to invagination
of the foot process membrane, to which CD2AP and nephrin are
recruited (60). In fact, a fully functioning podocin is required for
nephrin transport to the membrane (61). This is the foundation of
the slit diaphragm assembly (62). Between 10 and 28% of all non-
familial childhood, SRNS cases are caused by recessive podocin
mutations, such is the importance of this protein (62).
CD2AP is an adaptor molecule that possesses a coiled coil
domain and 3 Src homology 3 (SH3) domains (59, 63). It also
has an actin binding site at its NH2 terminus and is believed to
contribute to dynamic actin assembly (64, 65). CD2AP is capa-
ble of interacting with nephrin and in complex with nephrin and
podocin is able to recruit PI3K to the plasma membrane (63).
CONCLUSION
In reactive podocytopathies, the podocyte is injured by a circu-
lating factor (66). It is clear, however, that the podocytes undergo
a set of phenotypic and morphological changes during nephrotic
syndrome. This process has been likened to EMT. TGF-B1 is a
potent inducer of EMT. The research described in this review
has relied heavily on in vitro work centered on the response of
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FIGURE 1 | Podocyte structure and characteristics are shown. The
podocyte comprises three main compartments, the cell body, the major
processes, and the foot processes (A). Each of these segments shares a
common actin cytoskeleton. Neighboring foot processes regularly
interdigitate. The gap between these interdigitations is bridged by a
specialized cell–cell junction known as the slit diaphragm (C). Following
insult, the podocyte foot processes are effaced (B). This concomitantly
causes a loss of the slit diaphragm. The actin cytoskeleton is rearranged
and the podocyte is no longer able to restrict urinary protein loss. A
number of insults can cause the podocyte to lose its essential morphology
rendering it unable to perform as the final layer of the glomerular filtration
barrier. The number of slit diaphragms is reduced and the neat morphology
of the podocyte is lost in nephrotic syndrome. This is clearly demonstrated
by Patrakka et al. (68). (D) Epithelial and mesenchymal features of the
podocyte are shown. Epithelial and mesenchymal characteristics as
defined by Voulgari and Pintzas (40). The podocyte clearly possesses
features that are both epithelial and mesenchymal. Based on this
observation, it is not accurate to describe the podocyte as an epithelial
cell. Hence, describing podocyte dedifferentiation as EMT is also an
oversimplification.
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podocytes to TGF-B1 treatment. As demonstrated, the podocytes
do not undergo a typical type-2 EMT in response to TGF-B1. The
new term “podocyte disease transformation” has been coined in
order to distinguish this process from EMT.
A new technique known as transcriptome in vivo analysis
(TIVA), has been developed to analyze the transcriptome of sin-
gle cell populations in vivo without destroying the tissue (67).
This technique could be employed to further study the changes in
podocytes in disease models.
The traditional definition of a podocyte as an epithelial cell is
clearly simplistic, and in fact, this is a uniquely differentiated cell,
fit for a specific functional purpose that fulfills features of a par-
tial mesenchymal and partial epithelial cell. It reaches this mature
phenotype via immature mesenchymal and then epithelial stages,
and therefore, dedifferentiation in disease could result in regres-
sion to either of these states. It will be important in understanding
podocyte disease to understand the drivers of these changes, and
recognizing the developmental features that are correlated with
specific clinical conditions.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://www.frontiersin.org/Journal/10.3389/fendo.2014.00148/
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